Dear Every Cure community,

As we move into the fall, I’ve been thinking a lot about what it really takes to turn the promise of drug repurposing into impact for patients. Identifying a promising new use for an existing medicine is an incredibly important first step, but it’s only the beginning. At Every Cure, our goal is to see these opportunities all the way through — from identifying and evaluating them to building the evidence and working alongside patients, advocacy organizations, clinicians, and researchers to help treatments reach the people who need them.

This month, we’re sharing a few examples of what that looks like in practice. During Histiocytosis Awareness Month, we worked alongside the Histiocytosis Association to raise awareness of an important treatment option for Rosai-Dorfman disease and help more clinicians and patients learn about the updated NCCN guidelines. We also joined ARPA-H at Health250 to share the latest progress on our AI platform and how we’re working to turn promising discoveries into real-world impact.

None of this work happens alone. I’m incredibly grateful to the patients, clinicians, researchers, partners, and supporters who believe in this mission and help us move it forward every day. There’s so much more ahead, and I’m excited to keep building it together.

David Fajgenbaum, MD, MBA, MSc 

Co-Founder & CEO, Every Cure

September marked Histiocytosis Awareness Month, and we were proud to work with the Histiocytosis Association to raise awareness of Rosai-Dorfman disease (RDD) and an important update for patients. Earlier this year, Every Cure worked with Dr. Luke Chen and colleagues to evaluate and share the evidence supporting lenalidomide in combination with dexamethasone (len/dex) for RDD. That work contributed to an important milestone: the National Comprehensive Cancer Network (NCCN) updated its treatment guidelines, elevating len/dex to a preferred treatment option for RDD. Since then, our focus has been on helping ensure that patients who could benefit from this treatment are able to access it.

Throughout the month, we worked with the Histiocytosis Association to spread the word about the updated guidelines and joined clinicians and researchers from around the world at the Histiocyte Society Annual Meeting. These efforts reflect how we think about our work at Every Cure: identifying promising new uses for existing medicines is only the beginning. We work alongside clinicians, researchers, and patient organizations to help ensure strong evidence reaches the people who can act on it and, ultimately, the patients who could benefit. 

Histiocytosis Awareness Month may be over, but our work to increase awareness, adoption, and access to len/dex for RDD continues. Learn more about our work here.

Every Cure joined ARPA-H in Washington, DC, for Health250, its first-ever showcase of breakthrough health research. We had the opportunity to share the latest progress on MATRIX, our AI-powered platform for identifying promising new uses for existing medicines, and discuss a challenge at the heart of our work: finding a promising treatment is only the first step. We also need to break down the barriers that stand between that discovery and the patients who could benefit.

We’re incredibly grateful to the entire ARPA-H team for their continued belief in and support of Every Cure’s mission. Their partnership allows us to turn the promise of AI-powered drug repurposing into real progress for patients. See more here.

Our Chief Scientific Officer, Dr. Matt Goddeeris, recently joined Amy Sylvis on the Secrets to Abundant Living podcast to talk about how Every Cure is working to uncover new uses for existing medicines by bringing together AI, scientific research, and insights from patients and clinicians.

Matt shares the remarkable story of Bachmann-Bupp syndrome (BABS), an ultra-rare disease affecting only a small number of known patients worldwide, and how repurposing an existing medicine has changed the lives of children living with the disease. He also reflects on his own path from traditional biotech to Every Cure and why he chose to dedicate his career to finding treatments that might otherwise be overlooked. Listen to the full episode here. 

Over the past month, Every Cure has been recognized by leading organizations and media outlets — further helping to bring drug repurposing into the mainstream.

Click the photos below for the full stories.